Omar Nadeem, MD

Dr. Omar Nadeem, a Senior Physician at Dana-Farber and Assistant Professor at Harvard, shares cutting-edge developments in smoldering myeloma. He discusses how genomic profiling can refine risk stratification and highlight high-risk patients, allowing for personalized treatment. The role of innovative models like PANGEA and AI in dynamic risk assessment is explored, alongside exciting insights into bispecific antibodies and their early successes in trials. Dr. Nadeem emphasizes the shift towards early detection and intervention strategies to improve patient outcomes.